Cencora, Inc. (NYSE:COR) on Monday agreed to amass the bulk stake it doesn’t personal in OneOncology from TPG and different shareholders for.
The consideration consists of roughly $3.6 billion and retires its present company debt of $1.3 billion, for a complete consideration of roughly $5.0 billion.
OneOncology’s affiliated practices and administration will retain a minority curiosity in OneOncology.
The transaction values the OneOncology enterprise at $7.4 billion, with an fairness worth of roughly $6 billion.
OneOncology Funding
Cencora had an preliminary funding in OneOncology, a platform to allow neighborhood medical practices to stay unbiased and to enhance affected person entry to care of their communities, all at a decrease value than within the hospital setting.
The transaction is anticipated to shut by the tip of Cencora’s fiscal 2026 second quarter.
Cencora plans to fund the transaction by means of new debt financing, and monetary 2026 steering doesn’t at present embody the impression of the OneOncology acquisition.
Cencora expects the acquisition to be roughly impartial, web of financing prices, to Cencora’s adjusted diluted EPS within the first twelve months following shut.
In 2024, Cencora acquired Retina Consultants of America, a administration companies group (MSO) of retina specialists, from Webster Fairness Companions for $4.6 billion.
Fiscal 2026 Steerage Expectations
To mirror Cencora’s expectations for continued progress and execution, the corporate is reiterating its fiscal 2026 consolidated steering.
For 2026, the corporate expects gross sales progress of 5%-7% from 2025 gross sales of $321.3 billion.
In anticipation of the acquisition of OneOncology, the corporate mentioned it’s pausing share repurchases, and subsequently, it’s extra doubtless that the corporate’s full-year adjusted diluted EPS shall be in direction of the decrease half of its steering vary of $17.45 to $17.75.
Lengthy-Time period Steerage Expectations
Cencora is elevating its long-term steering for adjusted working earnings and adjusted diluted EPS to mirror the anticipated long-term contribution from including OneOncology to Cencora’s U.S. Healthcare Options phase.
The corporate expects adjusted working earnings progress of seven% to 10% from 6% to 9%, and adjusted earnings per share progress of 10% to 14% from 9% to 13%.
COR Worth Motion: Cencora shares have been up 0.05% at $346.16 throughout premarket buying and selling on Friday, in keeping with Benzinga Professional knowledge.
Learn Subsequent:
Photograph by JHVEPhoto by way of Shutterstock
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be part of our rising neighborhood at nextbusiness24.com
